Longtime Black Sabbath guitarist Tony Iommi has some big 2026 news to share as he reflected on all the big happenings in his world over the last 12 months for his New Year video message. The guitar ...

Watch the video below as Missouri football reporter Joey Van Zummeren gives his list of three underclassmen that provide reason to be encouraged about the team's future. After Missouri ended the 2025 ...

In romping in three of five starts, Knightsbridge has hinted at the promise of becoming a future stakes winner. The future could be now Dec. 27 at Gulfstream Park when Godolphin's homebred 4-year-old ...

This year marked a pivotal moment in the quest to treat Huntington’s disease, a rare but devastating form of dementia. Scientists found that an experimental gene therapy slowed the condition’s ...

A trio of large observational studies reported at the San Antonio Breast Cancer Symposium (SABCS) 2025 suggest that GLP-1 receptor agonists may improve outcomes in some women with breast cancer. Two ...

As Columbus city government debates whether it can continue funding the Columbus Promise program, how are the students participating in the program performing? On Dec. 10, The Dispatch reported that ...

When Chase Johnson was 31, her dog began acting strange. He was anxious, wouldn’t leave her side and, one day, pushed his nose into the side of her breast. Johnson felt a hard lump. “I wasn’t someone ...

(FOX40.COM) — Governor Gavin Newsom announced on Monday his commitment to housing equity and affordability by awarding the state $181.1 million in funding to focus on helping thousands of low-income ...

NEW YORK – At the American Society of Hematology's annual meeting this week, two groups of researchers from Spain’s Clinica Universidad de Navarra showed that circulating tumor cells (CTCs) may have ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...

Despite the considerable disease burden associated with hereditary hemorrhagic telangiectasia, no therapies are licensed for treatment. In a proof-of-concept, placebo-controlled trial, the ...